- Home
- RDVT vs AVBP Comparison
RDVT vs AVBP Comparison
Compare RDVT & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- AVBP
- Stock Information
- Founded
- RDVT 2017
- AVBP 2021
- Country
- RDVT United States
- AVBP United States
- Employees
- RDVT N/A
- AVBP N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- AVBP
- Sector
- RDVT Technology
- AVBP
- Exchange
- RDVT Nasdaq
- AVBP NYSE
- Market Cap
- RDVT 503.6M
- AVBP 617.4M
- IPO Year
- RDVT N/A
- AVBP 2024
- Fundamental
- Price
- RDVT $45.71
- AVBP $20.15
- Analyst Decision
- RDVT
- AVBP Strong Buy
- Analyst Count
- RDVT 0
- AVBP 6
- Target Price
- RDVT N/A
- AVBP $39.00
- AVG Volume (30 Days)
- RDVT 104.5K
- AVBP 158.1K
- Earning Date
- RDVT 05-07-2025
- AVBP 05-20-2025
- Dividend Yield
- RDVT 0.66%
- AVBP N/A
- EPS Growth
- RDVT N/A
- AVBP N/A
- EPS
- RDVT 0.61
- AVBP N/A
- Revenue
- RDVT $79,681,000.00
- AVBP N/A
- Revenue This Year
- RDVT $15.93
- AVBP $63.13
- Revenue Next Year
- RDVT $13.85
- AVBP N/A
- P/E Ratio
- RDVT $73.79
- AVBP N/A
- Revenue Growth
- RDVT 26.30
- AVBP N/A
- 52 Week Low
- RDVT $19.41
- AVBP $15.47
- 52 Week High
- RDVT $46.75
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- RDVT 73.39
- AVBP 51.13
- Support Level
- RDVT $38.00
- AVBP $18.84
- Resistance Level
- RDVT $40.10
- AVBP $21.79
- Average True Range (ATR)
- RDVT 1.73
- AVBP 1.12
- MACD
- RDVT 0.87
- AVBP 0.00
- Stochastic Oscillator
- RDVT 89.25
- AVBP 44.50
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.